Xeris Biopharma Holdings Inc (XERS)
3.225
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
3.23
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Revenue (Quarterly): 48.06M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 48.06M |
| March 31, 2024 | 40.64M |
| December 31, 2023 | 44.39M |
| September 30, 2023 | 48.32M |
| June 30, 2023 | 38.01M |
| March 31, 2023 | 33.20M |
| December 31, 2022 | 33.14M |
| September 30, 2022 | 29.72M |
| June 30, 2022 | 25.31M |
| March 31, 2022 | 22.07M |
| December 31, 2021 | 21.43M |
| September 30, 2021 | 11.06M |
| June 30, 2021 | 8.906M |
| March 31, 2021 | 8.195M |
| December 31, 2020 | 7.369M |
| Date | Value |
|---|---|
| September 30, 2020 | 9.404M |
| June 30, 2020 | 2.027M |
| March 31, 2020 | 1.676M |
| December 31, 2019 | 1.864M |
| September 30, 2019 | 0.313M |
| June 30, 2019 | 0.297M |
| March 31, 2019 | 0.248M |
| December 31, 2018 | 0.759M |
| September 30, 2018 | 0.582M |
| June 30, 2018 | 0.819M |
| March 31, 2018 | 0.263M |
| December 31, 2017 | 0.467M |
| September 30, 2017 | 0.17M |
| June 30, 2017 | 0.565M |
| March 31, 2017 | 0.354M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.676M
Minimum
Mar 2020
48.32M
Maximum
Sep 2023
22.88M
Average
22.07M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Zoetis Inc | 2.361B |
| Zevra Therapeutics Inc | 4.449M |
| NovaBay Pharmaceuticals Inc | 2.40M |
| Palatin Technologies Inc | 0.35M |
| iBio Inc | 0.175M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -15.00M |
| Total Expenses (Quarterly) | 56.25M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 634.18M |
| Gross Profit Margin (Quarterly) | 83.79% |
| Profit Margin (Quarterly) | -31.22% |
| Earnings Yield | -13.02% |
| Normalized Earnings Yield | -13.30 |